Oncolytic viruses for induction of anti-tumor immunity

Area of Science:

• Oncology
• Immunology
• Virology

Background:

• Oncolytic virotherapy is an emerging cancer treatment strategy utilizing engineered viruses for tumor cell destruction.
• Viruses offer distinct cell kill mechanisms, potentially overcoming resistance to traditional therapies like chemotherapy and radiotherapy.
• Emerging evidence highlights the crucial role of induced anti-tumor immune responses in the efficacy of oncolytic virotherapy.

Purpose of the Study:

• To investigate the contribution of immune activation to the clinical outcomes of oncolytic virotherapy.
• To evaluate the effectiveness of engineered adenoviral and herpes simplex virus constructs armed with granulocyte-macrophage colony-stimulating factor (GMCSF).
• To explore systemic delivery strategies for enhancing anti-tumor immunity.

Main Methods:

• Intratumoral administration of engineered adenoviral (AdΔ24) and herpes simplex virus (JS1/34.5-/47) constructs, both carrying a GMCSF payload.
• Clinical assessment of treatment response in advanced cancer patients.
• Analysis of innate and adaptive immune responses within the tumor microenvironment.

Main Results:

• Robust clinical response rates exceeding 25% were observed in advanced cancer patients treated with both viral constructs.
• Treatment resulted in regressions of both injected and distant, uninjected lesions, indicating systemic anti-tumor effects.
• The viral oncolysis mechanism was augmented by immune activation, leading to enhanced clinical outcomes.

Conclusions:

• Oncolytic virotherapy, particularly when combined with immune-stimulating payloads like GMCSF, demonstrates significant clinical efficacy in advanced cancers.
• Engineered viruses can induce systemic anti-tumor immune responses that contribute substantially to tumor elimination.
• Further research into systemic delivery methods is warranted to optimize the balance between viral clearance and tumor eradication through immune modulation.